US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

NUVB Panacea Acquisition Corp

3.03

0.04 (1.34%)

31 May 2024 - Cerrado

Retrasado por 15 minutos

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
ny20006177x2_ars.pdf

Panacea Acquisition (NYSE:NUVB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas Panacea Acquisition.

Panacea Acquisition (NYSE:NUVB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas Panacea Acquisition.

Noticias sobre Nuvation Bio Inc. NUVB

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Sábado 1 de Junio 2024 (1 día hace) • Business Wire

Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Miércoles 29 de Mayo 2024 (4 días hace) • Business Wire

Form PRER14A - Preliminary Proxy Soliciting materials
Viernes 24 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Viernes 24 de Mayo 2024 (1 semana hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Martes 14 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Martes 14 de Mayo 2024 (3 semanas hace) • Edgar (US Regulatory)

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Martes 14 de Mayo 2024 (3 semanas hace) • Business Wire

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Miércoles 24 de Abril 2024 (1 mes hace) • Business Wire

Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Miércoles 10 de Abril 2024 (2 meses hace) • Business Wire

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
Jueves 28 de Marzo 2024 (2 meses hace) • Business Wire

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
Lunes 25 de Marzo 2024 (2 meses hace) • Business Wire

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
Jueves 14 de Marzo 2024 (3 meses hace) • Business Wire

Más de Nuvation Bio Inc. Artículos de Noticias

Ibex Technologies (PK)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones